News | September 06, 2021
CRAMS to drive growth for Indian pharma industry: report
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The company has been sold to Shinshin Pharmaceuticals
Fitterfly has launched an online Prediabetes risk test which is an evidence-based, clinically validated tool for assessing an individual's risk of Prediabetes
Turnover of API division of ISLL stood at Rs 856.58 crore
It posted net loss of Rs.(2429.81) crores for the period ended June 30, 2020.
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
Apart from the above, it was also decided that Basic Customs Duty on import of COVID-19 vaccines be also exempted with immediate effect for a period of 3 months
Essential medicines were made available to more than 150 countries around the world during the pandemic
The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021.
Subscribe To Our Newsletter & Stay Updated
